Compare Moderna, Inc. (MRNA) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tapestry, Inc. — how do they compare? Moderna, Inc. trades at $205.17 (market cap $78.65B), while Tapestry, Inc. trades at $115.85 (market cap $23.09B). The key difference: Moderna, Inc. is far larger — about 3.4× Tapestry, Inc.'s market cap, and Tapestry, Inc. pays a 1.6% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Tapestry, Inc. for 70 Days on average.
| MRNA | TPR | |
|---|---|---|
Market Cap | $78.65B | $23.09B |
Volume | 37,373,437 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $164.78 |
52-Week Low | $22.36 | $98.81 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $74.80B | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
TPR trades at $113.39, down 2.86% today, with a bearish technical signal from moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined significantly to $183M from $816M in 2024. Recent earnings beats and a 73% analyst buy rating support optimism, while technical indicators show resistance near $114-116. The stock trades at a P/E of 15.93, below the consensus price target of $174.64.
Outlook remains positive based on analyst consensus and earnings momentum, but risks include Kate Spade execution challenges, tariff pressures, and volatile cash flows. The current price offers potential upside to targets, though technical weakness near-term requires monitoring support at $111-113. Revenue growth to $8B in 2026 with margin expansion could drive valuation if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
